Takeda engaged in antitrust scheme to delay generic constipation drug: US jury

[ad_1] (Reuters) — A U.S. jury on Monday found Takeda Pharmaceutical liable for causing about $885 million in damages by delaying a generic version of its constipation drug Amitiza through an anticompetitive scheme. Jurors in federal court in Boston, following a five-week trial, …

Takeda engaged in antitrust scheme to delay generic constipation drug: US jury Read More